News

Recent news about Panacea Capital and select portfolio companies

April 20, 2026

Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026

HiRO to Attend BIO Korea 2026, April 28–30 in Seoul HiRO is excited to announce…

April 20, 2026

Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026

HiRO to Attend BIO Korea 2026, April 28–30 in Seoul HiRO is excited to announce…

April 20, 2026

Meet HiRO at COG New England Conference on April 28-29!

HiRO to Attend COG New England Conference, April 28–29 Clinical development is becoming increasingly global,…

April 20, 2026

Meet HiRO at COG New England Conference on April 28-29!

HiRO to Attend COG New England Conference, April 28–29 Clinical development is becoming increasingly global,…

April 17, 2026

China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell and Gene Therapy

China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell…

April 17, 2026

China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell and Gene Therapy

China’s Order No. 818: What Foreign Biotech Companies Need to Know About IITs for Cell…

April 17, 2026

From China, Bridging Biopharmaceutical Innovation in Korea - Chime Biologics Empowers a New Landscape for Korea's Biopharma Industry

April 17, 2026

From China, Bridging Biopharmaceutical Innovation in Korea - Chime Biologics Empowers a New Landscape for Korea's Biopharma Industry

April 9, 2026

Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

April 9, 2026

Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe